Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis

Research output: Contribution to journalArticle

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.

Original languageEnglish (US)
Article number12
JournalDermatology Online Journal
Volume24
Issue number7
StatePublished - Jul 1 2018

Fingerprint

ocrelizumab
Dermatitis
Multiple Sclerosis
Autoimmune Diseases
B-Lymphocytes
Chronic Disease
Physicians
Therapeutics
Pharmaceutical Preparations

Keywords

  • Drug-induced psoriasiform dermatitis
  • Multiple sclerosis
  • Ocrelizumab
  • Psoriasiform dermatitis

ASJC Scopus subject areas

  • Dermatology

Cite this

Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis. / Darwin, Evan; Romanelli, Paolo; Lev-Tov, Hadar.

In: Dermatology Online Journal, Vol. 24, No. 7, 12, 01.07.2018.

Research output: Contribution to journalArticle

@article{6967303db96143a59326f2dccc6f0d72,
title = "Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis",
abstract = "Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.",
keywords = "Drug-induced psoriasiform dermatitis, Multiple sclerosis, Ocrelizumab, Psoriasiform dermatitis",
author = "Evan Darwin and Paolo Romanelli and Hadar Lev-Tov",
year = "2018",
month = "7",
day = "1",
language = "English (US)",
volume = "24",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "7",

}

TY - JOUR

T1 - Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis

AU - Darwin, Evan

AU - Romanelli, Paolo

AU - Lev-Tov, Hadar

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.

AB - Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.

KW - Drug-induced psoriasiform dermatitis

KW - Multiple sclerosis

KW - Ocrelizumab

KW - Psoriasiform dermatitis

UR - http://www.scopus.com/inward/record.url?scp=85053592738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053592738&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 7

M1 - 12

ER -